Introduction
The causes of end-stage renal disease (ESRD) in the United States Renal Data System (USRDS) database are provided by thousands of nephrologists without standardized diagnostic criteria and frequently without kidney biopsies. These diagnoses may not be accurate and physician bias plays a major role in disease classification [1] [2] [3] [4] [5] . When nephrologists were provided with identical clinical histories in nondiabetic patients having low-level proteinuria and hypertension, they were twice as likely to diagnose hypertensive kidney disease in African Americans and more likely to diagnose chronic glomerulonephritis in European Americans [6] . Nonetheless, nephropathy classified as secondary to hypertension is consistently reported as the second most common cause of ESRD in the USA [7] . Nearly one-third of African Americans initiating dialysis in the USA are labeled with hypertension-associated ESRD, in contrast to 25% of European Americans [7] .
Many attribute the excess frequency of hypertensive nephropathy in African Americans to the higher preva-lence and greater severity of high blood pressure, as well as lower socioeconomic status and poorer access to medical care. However, McClellan et al. [8] reported that ethnic differences in the relative risk of hypertensive renal failure persisted after adjustment for age, sex, and differences in prevalence and severity of hypertension between races. In addition, Rostand et al. [9] reported that hypertensive African Americans had twice the incidence of declining renal function than European Americans, despite similar initial serum creatinine concentration, initial and treated blood pressures, number of missed office visits and antihypertensive medications prescribed. The Multiple Risk Factor Intervention Trial (MRFIT) also detected a significant decline in kidney function in hypertensive African Americans compared with non-African Americans, despite equivalent hypertension control in both ethnic groups [10] . Pharmacologic treatment of mild-to-moderate hypertension in African Americans has little impact on the incidence of chronic renal failure, whereas it significantly reduces the progression of chronic kidney disease (CKD) in European Americans, along with treatment of hyperlipidemia and smoking cessation [10] [11] [12] .
If mild-to-moderate hypertension commonly caused kidney failure in African Americans, early and successful blood pressure control would be expected to reduce the incidence of renal functional decline [13] . However, the Hypertension Detection and Follow-up Program (HDFP), MRFIT, and African American Study of Kidney Disease and Hypertension (AASK) trials uniformly revealed that strict blood pressure control in hypertensive African Americans led to similar declines in renal function compared with standard blood pressure control, even using angiotensin-converting enzyme (ACE) inhibitors [10, 14, 15] .
When histopathology was available, African Americans clinically labeled with 'hypertensive nephrosclerosis' typically had focal global and/or focal segmental glomerulosclerosis [16, 17] . An important finding from the AASK study was that individuals who underwent kidney biopsy had fairly uniform histology with focal global glomerulosclerosis, interstitial fibrosis and renal microvascular changes, although only 39 patients were evaluated. The vascular changes historically ascribed to hypertension (intimal hyperplasia, luminal narrowing and thickening of the media in small intrarenal blood vessels) did not correlate with systemic blood pressure, suggesting that high blood pressure was not causative. These findings raised the possibility that a primary kidney disease was present and caused secondarily elevated blood pressure [17] .
Marcantoni et al. [18] compared the presence of renal histologic changes in European Americans and African Americans given the clinical diagnosis 'hypertensive nephrosclerosis'. Marked ethnic variation was observed, African Americans more often had solidified glomerulosclerosis and European Americans had obsolescent and collagen-rich glomerulosclerosis. African Americans with nondiabetic nephropathy were generally younger than European Americans, had similar mean arterial blood pressures, and more prominent arteriolosclerotic changes. The presence of ethnic differences in renal histology, coupled with the relentless renal functional decline in African Americans with treated hypertension, emphasize that the primary lesion in African Americans with 'hypertensive' nephropathy resides in the kidney. In contrast, treating small vessel disease in hypertensive European Americans by blood pressure lowering and reducing other cardiovascular disease risk factors suggests that hypertension truly initiates kidney disease in these patients.
That African Americans with hypertension and CKD more often progress to dialysis, whereas European Americans are more likely to die from cardiovascular causes is also interesting. This pattern suggests the presence of disparate disease processes between ethnic groups, with renal-limited diseases in African Americans accounting for less severe systemic atherosclerosis with improved survival [19 ] .
Genetic determinants of nondiabetic kidney disease
The major breakthrough in our understanding of common complex kidney disease came with identification of the association between the nonmuscle myosin heavy chain 9 gene (MYH9) and idiopathic and secondary forms of focal segmental glomerulosclerosis (FSGS). Marked familial aggregation of kidney disease is observed in African Americans, often with different causes of kidney disease in family members [20] . Familial aggregation occurs independently from socioeconomic factors [21, 22] , suggesting the presence of a generalized renal failure susceptibility gene. A major gene was recently discovered using Mapping by Admixture Linkage Disequilibrium, a technique valuable in admixed populations displaying ethnic differences in disease frequency. African Americans are an admixed population consisting of approximately 80% African and 20% European genetic make-up. African Americans have a four-fold or greater excess risk of allcause ESRD than European Americans [23] [24] [25] and have particularly high rates of HIV-associated nephropathy (HIVAN) and idiopathic FSGS [26] [27] [28] [29] .
Kopp et al. [30 ] initially identified excess African ancestry on chromosome 22p in African Americans with idiopathic FSGS and HIV-associated collapsing FSGS, compared with African Americans. Fine mapping under the admixture peak identified MYH9 as the associated gene. MYH9 was associated with clinically diagnosed 'hypertensive ESRD' in African Americans as well [30 ,31 ] . The Family Investigation in Nephropathy and Diabetes (FIND) study rapidly replicated association in several nondiabetic forms of ESRD in African Americans, including idiopathic FSGS, HIVAN and clinically diagnosed 'hypertensive-ESRD' [32 ] . The FIND study indicated that the population-attributable risk from MYH9 in African Americans with nondiabetic ESRD was 70% (70% of nondiabetic cases of ESRD in African Americans would disappear if MYH9 risk variants were replaced with the neutral/protective variants more often found in European-derived populations). These studies demonstrated that ethnic differences in susceptibility to nondiabetic ESRD were largely due to heredity, not socioeconomic factors or ethnic differences in access to care. Risk variants in MYH9 are present in 60% of all African Americans, in contrast to 4% of European Americans. Ethnic disparities in gene frequency account for much of the ethnic variation in risk for nondiabetic ESRD.
The importance of MYH9 in the disease historically labeled 'hypertensive ESRD' was extended in 696 patients who were diagnosed by their nephrologists, compared with 948 non-nephropathy controls recruited at Wake Forest [33 ] . Strong evidence of association was confirmed, with single-nucleotide polymorphism (SNP) odds ratios (ORs) as high as 3.4. Thus, the spectrum of MYH9-associated nephropathies in African Americans encompasses idiopathic FSGS, HIVAN, and those with the clinical diagnosis 'hypertensive ESRD'. MYH9 is an overarching renal failure susceptibility gene, acting independently from high blood pressure, hyperglycemia, and HIV infection. MYH9 was recently shown to underlie approximately 16% of type 2 diabetes-associated ESRD in African Americans, although it remains unclear whether the disease was FSGS with coincident diabetes or classic diabetic nephropathy [34 ] .
Does hypertension 'trigger' MYH9-associated kidney disease?
Confirmation that MYH9 was associated with ESRD in multiple African American cohorts raised the question of whether hypertension might cause ESRD in individuals inheriting two MYH9 risk variants. It was necessary to evaluate large numbers of African Americans and European Americans with essential hypertension and measures of proteinuria and kidney function to determine whether MYH9 was associated with elevated blood pressure in the absence of kidney disease. National Heart Lung and Blood Institute-sponsored Hypertension Genetics (HyperGEN) study samples were analyzed [35 ] . HyperGEN included nearly 1500 hypertensive African Americans and 1500 hypertensive European Americans with preserved kidney function and measures of albuminuria [36] . The most striking finding from HyperGEN was that MYH9 risk allele frequencies were no different in hypertensionenriched cohorts than ethnically matched general populations [35 ] . Moreover, MYH9 was weakly associated with albuminuria in hypertensive African Americans, but not in hypertensive European Americans, an effect likely related to inclusion of small numbers of individuals with pre-existing FSGS, as mild-to-moderate CKD was not an exclusion criterion.
To convince those skeptical that high blood pressure does not frequently cause kidney disease in African Americans, it was important to test for MYH9 gene associations in cases fitting rigorous clinical criteria for hypertensive nephropathy. AASK participants were ideal, since they were uniformly hypertensive, lacked diabetes and had a maximum of 2.5 g of urinary protein excretion per day. Four MYH9 SNPs have been evaluated in 497 AASK participants. SNP rs4821481, located in the E1 haplotype that is strongly associated with FSGS, HIVAN and 'hypertensive ESRD', was strongly associated with kidney disease in AASK participants (OR 1.63; P ¼ 6.5 Â 10 À5 , recessive). Increasing strength of association was detected in AASK participants with progressive nephropathy and serum creatinine concentrations exceeding 3 mg/dl (OR 2.33; P ¼ 2.4 Â 10 À6 , recessive) [37] . Among the 161 AASK patients with serum creatinine concentrations of at least 3 mg/dl, MYH9 SNPs rs11912763 (OR 2.69; P ¼ 0.008, recessive) and rs1005570 (OR 1.57; P ¼ 0.027, recessive) were also strongly associated.
The spectrum of MYH9-associated kidney diseases in African Americans now extends from clinically diagnosed hypertensive nephropathy with focal global glomerulosclerosis and interstitial fibrosis on biopsy in AASK participants to ESRD historically attributed to hypertension. Moreover, MYH9 exhibits the strongest disease association yet detected for common complex human diseases, as seen in idiopathic FSGS and HIVAN. The magnitude of association reveals the presence of a Mendelian-like effect in nondiabetic kidney disease. MYH9 is also strongly associated with idiopathic FSGS in European Americans and development of CKD in Europeans [30 ,38 ] . However, the frequency of kidney disease related to MYH9 in European-derived populations is far lower than in African Americans due to the reduced frequency of risk alleles. Finally, chromogranin A gene (CHGA) polymorphisms are also associated with hypertensive ESRD in African Americans [39 ,40] .
Myosin and MYH9
The MYH9 gene encodes nonmuscle myosin class II isoform IIA [41] . Myosins constitute a superfamily of proteins interacting with actin and grouped into 15 classes [42] . Myosin class II is subdivided into smooth and nonsmooth muscle myosin II. These myosins are structurally similar and composed of two heavy and two light chains that polymerize and interact with actin. Nonmuscle myosin heavy chains (NMMHCs) exist in three isoforms (NMMHC-A, NMMHC-B, NMMHC-C), each encoded by different genes (MYH9, MYH10 and MYH14, respectively, on chromosomes 22q12.3, 17p13.3, and 19p13.3) [43] , subdividing nonsmooth muscle myosin II into three isoforms: IIA, IIB, and IIC [42] .
Nonsmooth muscle myosin II isoforms are variably expressed in different tissues. Platelets express only NMMHC-A (II-A) [44] , whereas fetal and adult human kidneys express isoforms IIA and IIB [43, 45] . Isoform IIA is expressed mainly in glomeruli of mature kidneys (podocytes and mesangial cells) and arteriolar and peritubular capillaries [43, 45] . Within podocytes, MYH9 protein localizes mainly in the foot processes as a continuous narrow layer underneath the plasma membrane [45] .
Myosin IIA is involved in cellular contractility, migration, phagocytosis, actin stress fiber organization, maintenance of cell shape and polarity, cell-cell contact and focal adhesion, and intracellular organelle trafficking [46, 47] .
Alterations in myosin IIA protein are clearly relevant to human disease. Heterozygous mutations in MYH9 cause the MYH9-related disease spectrum (MYH9-RD) including May-Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein syndrome as shown below [48] .
(1) Idiopathic FSGS.
(2) Focal global glomerulosclerosis (previously labeled 'hypertensive renal disease'). [48] . Renal disease in these related syndromes manifests as glomerulopathy with hematuria, proteinuria, and progressive renal failure with ESRD in the fifth decade, although it has been reported in childhood [49] . Histologic data are scanty and include mesangial matrix expansion, mesangial cell proliferation, podocyte foot process effacement, variable degrees of capillary wall basement membrane thickening and basket-weave splitting, leading to global glomerulosclerosis in a case report containing repeat kidney biopsies [49] . Wide phenotypic variability is seen, with single mutations in a family or unrelated individuals causing a spectrum of renal manifestations [45] . This fostered the concept that MYH9 syndromes are not distinct entities, but a single disorder with variable manifestations [48] .
MYH9 and glomerulosclerosis: potential pathogenetic mechanisms
A healthy podocyte cytoskeleton is required to maintain cellular architecture and fulfill the filtration barrier function [50, 51] . Mutations in genes encoding podocyte proteins interacting with the actin cytoskeleton, including alpha-actinin 4 [52] , CD2-associated protein [53] and synaptopodin [54] are associated with FSGS. Myosin IIA is a component protein of the podocyte cytoskeleton [55] . Dysregulated podocyte myosin function and consequent actin cytoskeleton abnormalities might lead to inability to withstand hydraulic pressure and maintain capillary integrity, foot process retraction, quantitative diminution of glomerular basement membrane collagen IV synthesis [45, 56] , and resultant glomerulosclerosis.
Epithelial tissues depend heavily on cell-cell adhesions, requiring correct localization of junctional components such as E-cadherin, zonula occludens and b-catenin for function. Myosin II is critical for concentrating E-cadherin at these sites [57] and loss of E-cadherin may be involved in epithelial-mesenchymal transition (EMT) [58] . Glomerular EMT has been proposed as important in the development of glomerular disease [59, 60] and provides a possible link between MYH9 and glomerulosclerosis.
Platelet influx in the glomerulus has also been implicated in glomerulosclerosis and glomerular obsolescence in animal models using renal ablation [61] [62] [63] . As MYH9 polymorphisms are associated with syndromes characterized by abnormal platelet size and function [64] , glomerular platelet accumulation with resultant ischemia and release of transforming growth factor (TGF)-b and platelet-derived growth factor (PDGF) could potentiate MYH9-associated nephropathy [65, 66] .
Gene-gene and gene-environment interactions in MYH9 nephropathy
Although MYH9 demonstrates strong association with human disease, inheriting two MYH9 risk variants appears insufficient to initiate nephropathy. Approximately 4% of African Americans inheriting two MYH9 risk variants developed idiopathic FSGS, whereas approximately 20% with HIV infection and two risk variants developed collapsing FSGS or HIVAN (J. Kopp, personal communication) . This demonstrates that HIV1 viral infection, an environmental factor, yields a five-fold increase in risk. Importantly, approximately 80% of genetically susceptible African Americans with HIV infection will not develop HIVAN and 96% of HIV-negative African American risk homozygotes will not develop FSGS. In the absence of HIV infection, C1q nephropathy can also manifest a collapsing phenotype in the presence of MYH9 risk variant homozygosity [67] . This strongly implicates a 'second hit' whereby individuals with genetic susceptibility to kidney disease require an additional factor(s) to initiate nephropathy. We believe that MYH9 gene-gene and MYH9 gene-environment interactions exist (Fig. 1) . For example, it will be important to evaluate MYH9 gene products for interaction with podocin and other proteins constituting the podocyte cytoskeleton and slit diaphragm.
Environmental factors such as HIV infection can clearly trigger MYH9-associated nephropathy. It will be important to evaluate the roles of nephropathic viruses including polyoma viruses and parvovirus B19. It is also possible that lymphotropic viruses related to HIV1 initiate kidney disease in susceptible African Americans and HTLV-1, HTLV-2, cytomegalovirus, and human herpes virus 6 are prime candidates, although HIV1 directly infects podocytes.
These possibilities provide new hope for preventing kidney disease in those with genetic predisposition from MYH9. If viral infections initiate glomerulosclerosis, vaccines preventing infection could prevent renal insufficiency. As aggressive blood pressure control and use of ACE inhibitors fail to halt progression of MYH9-associated kidney diseases, novel strategies to maintain podocyte cytoskeletal architecture have the potential to prevent glomerulosclerosis in African Americans with the disorder that has historically been labeled hypertensive nephrosclerosis.
Conclusion
Longstanding physician bias and misclassification have confused the classification of chronic forms of nephropathy. High blood pressure is not a common inciting factor for hypertensive nephrosclerosis in African Americans. In contrast, small vessel disease related to high blood pressure and other cardiovascular risk factors is often present in older European Americans given this diagnosis. Nonetheless, it remains critical to aggressively treat high blood pressure in those with (and at risk for) kidney disease. Hypertension accelerates nephropathy progression in all proteinuric kidney diseases [68] and contributes to heart failure, myocardial infarction and stroke [69] [70] [71] . Seventy percent of African Americans with nondiabetic kidney disease fall into the spectrum of MYH9-associated nephropathy, ranging from focal global glomerulosclerosis in AASK participants, to sporadic FSGS, to collapsing glomerulopathy related to HIV infection. It is unclear why these different histologic disease patterns develop, although it is tempting to speculate that different modifier genes or environmental factors interacting with MYH9 dictate renal lesions. These recent genetic studies made major contributions toward untangling the complex relationship between high blood pressure and initiation of kidney disease. MYH9-related podocyte cytoskeleton dysregulation with progressive nephron loss likely causes secondary hypertension in African Americans labeled as having hypertensive nephropathy. 
